

Michael J Selgelid

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8854587/publications.pdf>

Version: 2024-02-01

86
papers

1,699
citations

361045

20
h-index

329751

37
g-index

98
all docs

98
docs citations

98
times ranked

1384
citing authors

#	ARTICLE	IF	CITATIONS
1	Reconciling Regulation with Scientific Autonomy in Dual-Use Research. <i>Journal of Medicine and Philosophy</i> , 2022, 47, 72-94.	0.4	4
2	Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop. <i>Vaccine</i> , 2022, 40, 3484-3489.	1.7	6
3	Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group. <i>Vaccine</i> , 2021, 39, 633-640.	1.7	42
4	Human Challenge Studies in Endemic Settings. <i>SpringerBriefs in Ethics</i> , 2021, , .	0.6	22
5	Case Studies: Challenge Studies in Low- and Middle-Income Countries. <i>SpringerBriefs in Ethics</i> , 2021, , 103-127.	0.6	3
6	Ethical issues surrounding controlled human infection challenge studies in endemic low- and middle-income countries. <i>Bioethics</i> , 2020, 34, 797-808.	0.7	19
7	Coronavirus Human Infection Challenge Studies: Assessing Potential Benefits and Risks. <i>Journal of Bioethical Inquiry</i> , 2020, 17, 709-715.	0.9	6
8	COVID-19 human challenge studies: ethical issues. <i>Lancet Infectious Diseases</i> , The, 2020, 20, e198-e203.	4.6	91
9	Human infection challenge studies in endemic settings and/or low-income and middle-income countries: key points of ethical consensus and controversy. <i>Journal of Medical Ethics</i> , 2020, 46, 601-609.	1.0	20
10	Should practice and policy be revised to allow for risk-proportional payment to human challenge study participants?. <i>Journal of Medical Ethics</i> , 2020, 46, 835-836.	1.0	7
11	Invisible epidemics: ethics and asymptomatic infection. <i>Monash Bioethics Review</i> , 2020, 38, 1-16.	0.4	4
12	Drug-Resistant Infection: Causes, Consequences, and Responses. <i>Public Health Ethics Analysis</i> , 2020, , 3-18.	0.1	11
13	Surveillance and Control of Asymptomatic Carriers of Drug-Resistant Bacteria. <i>Public Health Ethics Analysis</i> , 2020, , 183-201.	0.1	0
14	Surveillance and control of asymptomatic carriers of drug-resistant bacteria. <i>Bioethics</i> , 2019, 33, 766-775.	0.7	9
15	Is the non-identity problem relevant to public health and policy? An online survey. <i>BMC Medical Ethics</i> , 2019, 20, 46.	1.0	5
16	Impartiality and infectious disease: Prioritizing individuals versus the collective in antibiotic prescription. <i>AJOB Empirical Bioethics</i> , 2019, 10, 63-69.	0.8	4
17	Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e31-e38.	4.6	120
18	Ethics, health policy, and Zika: From emergency to global epidemic?. <i>Journal of Medical Ethics</i> , 2018, 44, 343-348.	1.0	9

#	ARTICLE	IF	CITATIONS
19	Ethical challenges posed by human infection challenge studies in endemic settings. <i>Indian Journal of Medical Ethics</i> , 2018, III, 274-278.	0.2	22
20	The World Health Organization, Public Health Ethics, and Surveillance: Essential Architecture for Social Well-Being. <i>American Journal of Public Health</i> , 2017, 107, 1596-1598.	1.5	7
21	Zika, contraception and the non-identity problem. <i>Developing World Bioethics</i> , 2017, 17, 173-204.	0.6	3
22	Necessity and least infringement conditions in public health ethics. <i>Medicine, Health Care and Philosophy</i> , 2017, 20, 525-535.	0.9	11
23	Ethics of public health surveillance: new guidelines. <i>Lancet Public Health</i> , The, 2017, 2, e348-e349.	4.7	16
24	Victims, vectors and villains: are those who opt out of vaccination morally responsible for the deaths of others?. <i>Journal of Medical Ethics</i> , 2016, 42, 762-768.	1.0	23
25	Ethics, Climate Change and Infectious Disease. <i>Public Health Ethics Analysis</i> , 2016, , 59-75.	0.1	5
26	Gain-of-Function Research: Ethical Analysis. <i>Science and Engineering Ethics</i> , 2016, 22, 923-964.	1.7	49
27	Capabilities and Incapabilities of the Capabilities Approach to Health Justice. <i>Bioethics</i> , 2016, 30, 25-33.	0.7	0
28	Practical bioethics. <i>Monash Bioethics Review</i> , 2016, 34, 1-2.	0.4	0
29	Ethical Criteria for Human Challenge Studies in Infectious Diseases: Table 1.. <i>Public Health Ethics</i> , 2016, 9, 92-103.	0.4	84
30	Synthetic Biology. , 2016, , 2775-2783.		0
31	A relational approach to saviour siblings?. <i>Journal of Medical Ethics</i> , 2015, 41, 924-925.	1.0	1
32	Burden of Proof in Bioethics. <i>Bioethics</i> , 2015, 29, 597-603.	0.7	11
33	Ethical aspects of malaria control and research. <i>Malaria Journal</i> , 2015, 14, 518.	0.8	31
34	Biosecurity and Open-Source Biology: The Promise and Peril of Distributed Synthetic Biological Technologies. <i>Science and Engineering Ethics</i> , 2015, 21, 1065-1083.	1.7	24
35	Conflicting clinical duties. <i>Journal of Medical Ethics</i> , 2015, 41, 213-214.	1.0	0
36	Freedom and moral enhancement. <i>Journal of Medical Ethics</i> , 2014, 40, 215-216.	1.0	7

#	ARTICLE	IF	CITATIONS
37	Editorial. Monash Bioethics Review, 2014, 32, 159-161.	0.4	0
38	Ethical and Empirical Issues Concerning Conditional Treatment of Lead Poisoning from Gold Mining in Nigeria. Public Health Ethics, 2014, 7, 306-307.	0.4	0
39	Dual Use. , 2014, , 641-648.		0
40	Placebo use in vaccine trials: Recommendations of a WHO expert panel. Vaccine, 2014, 32, 4708-4712.	1.7	45
41	Moderate eugenics and human enhancement. Medicine, Health Care and Philosophy, 2014, 17, 3-12.	0.9	17
42	Ethical considerations for vaccination programmes in acute humanitarian emergencies. Bulletin of the World Health Organization, 2013, 91, 290-297.	1.5	38
43	Biodefense and dual-use research: the optimisation problem and the value of security. Journal of Medical Ethics, 2013, 39, 205-206.	1.0	1
44	Moral uncertainty and the moral status of early human life. Journal of Medical Ethics, 2013, 39, 324.1-324.	1.0	1
45	The Case for Mandatory Flu Vaccination of Children. American Journal of Bioethics, 2013, 13, 38-40.	0.5	5
46	The role of informed consent in tuberculosis testing and screening. European Respiratory Journal, 2012, 39, 1057-1059.	3.1	3
47	Moral uncertainty and the moral status of early human life. Monash Bioethics Review, 2012, 30, 52-57.	0.4	6
48	Justice, infectious diseases and globalization. , 2011, , 89-96.		44
49	The mousepox experience. EMBO Reports, 2010, 11, 18-24.	2.0	14
50	Back to the future: Controlling synthetic life science trade in DNA sequences. Bulletin of the Atomic Scientists, 2010, 66, 9-20.	0.2	1
51	Reflections on the Synthetic Production of Poliovirus. Bulletin of the Atomic Scientists, 2010, 66, 1-9.	0.2	13
52	Populations, Patients, Germs and Genes: Ethics Of Genomics and Informatics in Communicable Disease Control. , 2010, , 397-418.		2
53	Promoting Justice, Trust, Compliance, and Health: The Case for Compensation. American Journal of Bioethics, 2009, 9, 22-24.	0.5	6
54	A Moderate Pluralist Approach to Public Health Policy and Ethics. Public Health Ethics, 2009, 2, 195-205.	0.4	43

#	ARTICLE	IF	CITATIONS
55	Dual-Use Research Codes of Conduct: Lessons from the Life Sciences. <i>NanoEthics</i> , 2009, 3, 175.	0.5	22
56	Infectious Disease Ethics: Limiting Liberty in Contexts of Contagion. <i>Journal of Bioethical Inquiry</i> , 2009, 6, 149-152.	0.9	6
57	Professionalization as a governance strategy for synthetic biology. <i>Systems and Synthetic Biology</i> , 2009, 3, 91-97.	1.0	12
58	Managing the unimaginable. <i>EMBO Reports</i> , 2009, 10, 7-11.	2.0	21
59	Pandethics. <i>Public Health</i> , 2009, 123, 255-259.	1.4	49
60	Governance of dual-use research: an ethical dilemma. <i>Bulletin of the World Health Organization</i> , 2009, 87, 720-723.	1.5	43
61	Dual-Use Research Codes of Conduct: Lessons from the Life Sciences. , 2009, , 135-143.		0
62	Michael L. Gross, Bioethics and Armed Conflict: Moral Dilemmas of Medicine and War. <i>Minerva</i> , 2008, 46, 381-384.	1.4	1
63	IMPROVING GLOBAL HEALTH: COUNTING REASONS WHY. <i>Developing World Bioethics</i> , 2008, 8, 115-125.	0.6	55
64	INFECTIOUS DISEASES, SECURITY AND ETHICS: THE CASE OF HIV/AIDS. <i>Bioethics</i> , 2008, 22, 457-465.	0.7	19
65	Specifying the Duty to Treat. <i>American Journal of Bioethics</i> , 2008, 8, 26-27.	0.5	5
66	Just Liability and Reciprocity Reasons for Treating Wounded Soldiers. <i>American Journal of Bioethics</i> , 2008, 8, 19-21.	0.5	8
67	Ethical and Philosophical Consideration of the Dual-Use Dilemma in the Biological Sciences. , 2008, , .		57
68	TB Matters More. <i>International Library of Ethics, Law, and the New Medicine</i> , 2008, , 233-247.	0.5	1
69	Research Priorities, Profits, and Public Goods: The Case of Drug Resistant Disease. , 2007, , 27-38.		0
70	ETHICS AND DRUG RESISTANCE. <i>Bioethics</i> , 2007, 21, 218-229.	0.7	118
71	Pathologies of Power: Health, Human Rights, and the New War on the Poor ? By Paul Farmer. <i>Developing World Bioethics</i> , 2007, 7, 114-116.	0.6	0
72	A Tale of Two Studies: Ethics, Bioterrorism, and the Censorship of Science. <i>Hastings Center Report</i> , 2007, 37, 35-43.	0.7	61

#	ARTICLE	IF	CITATIONS
73	Ethical and Philosophical Consideration of the Dual-use Dilemma in the Biological Sciences. <i>Science and Engineering Ethics</i> , 2007, 13, 523-580.	1.7	108
74	The importance of "throwing money at" the problem of global health. <i>Indian Journal of Medical Ethics</i> , 2007, 4, 73-5.	0.2	3
75	Taking sociology seriously: a new approach to the bioethical problems of infectious disease. <i>Sociology of Health and Illness</i> , 2006, 28, 838-849.	1.1	14
76	Commentary: The Ethics of Dangerous Discovery. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2006, 15, .	0.5	2
77	MODULE FOUR: STANDARDS OF CARE AND CLINICAL TRIALS. <i>Developing World Bioethics</i> , 2005, 5, 55-72.	0.6	5
78	UNIVERSAL NORMS AND CONFLICTING VALUES. <i>Developing World Bioethics</i> , 2005, 5, 267-273.	0.6	13
79	ETHICS AND INFECTIOUS DISEASE1. <i>Bioethics</i> , 2005, 19, 272-289.	0.7	122
80	Focus on infectious disease. <i>Poiesis & Praxis</i> , 2005, 3, 227-228.	0.3	0
81	Democratic Defense Spending in an Age of Bioterrorism. <i>American Journal of Bioethics</i> , 2005, 5, 49-50.	0.5	2
82	Ethics, Economics, and Aids in Africa. <i>Developing World Bioethics</i> , 2004, 4, 96-105.	0.6	5
83	Smallpox Revisited?. <i>American Journal of Bioethics</i> , 2003, 3, 5-11.	0.5	11
84	Eugenic abortion, moral uncertainty, and social consequences. <i>Monash Bioethics Review</i> , 2001, 20, 26-42.	0.4	6
85	Neugenics?. <i>Monash Bioethics Review</i> , 2000, 19, 9-33.	0.4	4
86	Bioterrorism, Society and Health Care Ethics. , 0, , 631-637.		0